Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens

Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens

<p>Traditional vaccine development strategies are costly and time-consuming which makes them unsuitable for clinical assessment of new vaccines in the context of infectious diseases outbreaks. Platform technologies provide substantial manufacturing advantages and have the potential to signific...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Moreira Folegatti, P
Бусад зохиолчид:	Gilbert, S
Формат:	Дипломын ажил
Хэл сонгох:	English
Хэвлэсэн:	2021
Нөхцлүүд:	Vaccine Clinical Development

Ижил төстэй зүйлс

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
-н: Adam Berg, зэрэг
Хэвлэсэн: (2021-10-01)

Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV
-н: Charlotte Davis, зэрэг
Хэвлэсэн: (2024-06-01)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
-н: Zhang, C, зэрэг
Хэвлэсэн: (2023)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
-н: Cheng Zhang, зэрэг
Хэвлэсэн: (2023-06-01)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
-н: Natalie Gabrielle Marchevsky, зэрэг
Хэвлэсэн: (2022-07-01)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
-н: Pedro M. Folegatti, зэрэг
Хэвлэсэн: (2019-05-01)

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
-н: Hannah R. Sharpe, зэрэг
Хэвлэсэн: (2022-03-01)

Thromboses of major arteries and ChAdOx1 nCov-19 vaccination
-н: Rujittika Mungmunpuntipantip, зэрэг
Хэвлэсэн: (2021-11-01)

Impact of Improper Storage of ChAdOx1-S (AstraZeneca) Vaccine on Its Efficacy and Safety
-н: Marek Mikołajczyk, зэрэг
Хэвлэсэн: (2022-12-01)

Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines
-н: César López-Camacho, зэрэг
Хэвлэсэн: (2020-06-01)

Population-wide persistent hemostatic changes after vaccination with ChAdOx1-S
-н: Bas de Laat, зэрэг
Хэвлэсэн: (2022-07-01)

ChAdOx1 vaccination, blood coagulation, and inflammation: No effect on coagulation but increased interleukin‐6
-н: Loes H. Willems, зэрэг
Хэвлэсэн: (2021-12-01)

Effectiveness of the chAdOx1 nCoV-19 vaccine in preventing COVID-19 infection
-н: Tarana Sarwat, зэрэг
Хэвлэсэн: (2022-01-01)

Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
-н: Salma Al Bahrani, зэрэг
Хэвлэсэн: (2021-09-01)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
-н: Folegatti, P, зэрэг
Хэвлэсэн: (2019)

A rare case of bilateral optic neuritis post-Covishield (ChAdOx1-S [recombinant]) vaccination
-н: Tanie Natung, зэрэг
Хэвлэсэн: (2023-01-01)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
-н: Simone Barocci, зэрэг
Хэвлэсэн: (2022-03-01)

Neutralizing Antibody and T-Cell Responses against SARS-CoV-2 Wild-Type and Variants of Concern in Chronic Obstructive Pulmonary Disease Subjects after ChAdOx-1/ChAdOx-1 Homologous Vaccination: A Preliminary Study
-н: Warawut Chaiwong, зэрэг
Хэвлэсэн: (2022-12-01)

Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine
-н: Lea Krutzke, зэрэг
Хэвлэсэн: (2022-07-01)

IgA Vasculitis Following ChAdOx1 nCoV-19 Vaccination
-н: Manabendra Basu, зэрэг
Хэвлэсэн: (2024-01-01)

LGI-1 encephalopathy following ChAdOx1 nCov-19 vaccination
-н: Tamara Garibashvili, зэрэг
Хэвлэсэн: (2022-06-01)

Heterologous vaccination (ChAdOx1 and BNT162b2) induces a better immune response against the omicron variant than homologous vaccination
-н: Jaeeun Yoo, зэрэг
Хэвлэсэн: (2023-10-01)

Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine
-н: Edmund G.-T. Wee, зэрэг
Хэвлэсэн: (2024-08-01)

Vaccine‐induced immune thrombotic thrombocytopenia with ChAdOx1 nCoV‐19 is rare in Asia
-н: Kochawan Boonyawat, зэрэг
Хэвлэсэн: (2022-01-01)

DIC-Like Syndrome Following Administration of ChAdOx1 nCov-19 Vaccination
-н: Gerardo Casucci, зэрэг
Хэвлэсэн: (2021-06-01)

ChAdOx1 nCoV-19 Vaccine Side Effects among Healthcare Workers in Trinidad and Tobago
-н: Chavin D. Gopaul, зэрэг
Хэвлэсэн: (2022-03-01)

Secondary Immune Thrombocytopenia (ITP) Associated with ChAdOx1 Covid-19 Vaccination – A Case Report
-н: Martin Koch, зэрэг
Хэвлэсэн: (2021-07-01)

Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity
-н: Larissa Henze, зэрэг
Хэвлэсэн: (2023-01-01)

Sarcoidosis presenting as bilateral optic neuritis after ChAdOx1 nCoV-19 vaccination
-н: Amarendra Kumar Shukla, зэрэг
Хэвлэсэн: (2022-06-01)

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
-н: Wang-Huei Sheng, зэрэг
Хэвлэсэн: (2022-04-01)

Association of Reactogenicity with Immunogenicity of the ChAdOx1 nCoV-19 Vaccine in Patients Undergoing Hemodialysis
-н: Ting-Yun Lin, зэрэг
Хэвлэсэн: (2022-08-01)

AstraZeneca ChAdOx1-S COVID-19 vaccine can be safely administered in patients with EDTA allergy
-н: Syed B. Ali, зэрэг
Хэвлэсэн: (2022-03-01)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
-н: Hermosilla, E, зэрэг
Хэвлэсэн: (2022)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
-н: Eduardo Hermosilla, зэрэг
Хэвлэсэн: (2022-03-01)

Antibody Detection in Healthcare Workers after Vaccination with Two Doses of the BNT162b2 or ChAdOx1 Vaccine
-н: Kyoung Ho Roh, зэрэг
Хэвлэсэн: (2022-09-01)

Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan
-н: Jer-Hwa Chang, зэрэг
Хэвлэсэн: (2022-02-01)

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity
-н: Jinnam Kim, зэрэг
Хэвлэсэн: (2023-04-01)

Adult-onset Still's disease after ChAdOx1 nCoV-19 vaccine: a possible association
-н: Laíssa Fiorotti Albertino, зэрэг
Хэвлэсэн: (2022-11-01)

HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV
-н: Tamsin Cargill, зэрэг
Хэвлэсэн: (2023-11-01)

New Onset of Giant Cell Arteritis following ChAdOx1-S (Vaxevria<sup>®</sup>) Vaccine Administration
-н: Luca Lo Sardo, зэрэг
Хэвлэсэн: (2023-02-01)